Visirna

Visirna was founded in 2022 and established a strategic partnership with Arrowhead Pharmaceuticals (NASDAQ:ARWR), an internationally leading small nucleic acid drug company. The company’s current product pipeline includes three small nucleic acid (siRNA) drugs in clinical development targeting the cardiovascular and metabolic fields. Additionally, the company possesses independent R&D capabilities and will explore advancements in intrahepatic and extrahepatic delivery technologies as well as broader therapeutic areas. Its existing pipeline holds a leading position among similar competing products, supported by clear genomic and biological evidence for its targets, utilizing Arrowhead's proven delivery and chemical modification technology platforms. The company adopts a U.S.-China collaborative clinical development and registration strategy, which helps accelerate product launches.